Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20257085 | 0.90 | HRH3 (0.59) | ALDH1A1SMN1; SMN2HRH3HRH4BCHE | |
| SCHEMBL13726788 | 0.90 | HRH3 (0.59) | ALDH1A1SMN1; SMN2HRH3HRH4BCHE | |
| SCHEMBL8244556 | 0.85 | HRH3 (0.54) | ALDH1A1HRH3HRH4POLBMEN1 | |
| SCHEMBL16254956 | 0.85 | GAA (0.58) | ALDH1A1HRH3HRH4 | |
| SCHEMBL13727922 | 0.85 | GAA (0.58) | ALDH1A1HRH3HRH4 | |
| SCHEMBL82814 | 0.85 | HPGD (0.60) | ALDH1A1HRH3HRH4POLBBCHE | |
| SCHEMBL13726832 | 0.85 | HPGD (0.60) | ALDH1A1HRH3HRH4POLBBCHE | |
| SCHEMBL6189062 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HRH3HRH4HPGD | |
| SCHEMBL5304179 | 0.83 | CYP3A4 (0.66) | ALDH1A1SMN1; SMN2HRH3HRH4ACHE | |
| SCHEMBL12717 | 0.83 | CYP3A4 (0.66) | ALDH1A1SMN1; SMN2HRH3HRH4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | ALDH1A1 2156/4885SMN1; SMN2 208/4885HRH3 756/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | ALDH1A1 2156/4885SMN1; SMN2 208/4885HRH3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.